Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPERO: Propranolol for Epistaxis in HHT
NCT04113187Phase 3Terminated
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) comparing Propranolol arm with Placebo arm (2 arms). Primary endpoint: Cumulative duration of epistaxis at 6 months. Started Jun 2020; status: terminated.
02
Drugs
propranolol
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT04113187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04113187.